Effectiveness of adding nitazoxanide to the standard triple therapy in the eradication of Helicobacter pylori infection

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202112686695509

Enrollment

210

Registered

2021-12-01

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

amoxicillin based standard triple therapy

Metronidazole based standard triple therapy

Nitazoxanide based triple therapy

Standard triple therapy plus nitazoxanide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Any Naive Patient above the age of 18 years old with H.pylori infection will be included in the study. Patients infected by H.pylori will be diagnosed by stool antigen test.

Exclusion criteria

Exclusion criteria: Patients aged less than 18 years, prior gastric surgery, Prior H. pylori eradication therapy, recent intake of antibiotics, proton pump inhibitor (PPI), histamine (H2) receptor blockers, nonsteroidal or anti-inflammatory drugs within the last month, known allergy of any of the antibiotics used in the study, gastrointestinal malignancy, active upper gastrointestinal bleeding, pregnant and lactating women will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
The eradication rate of H. pylori infection	—

Secondary

Measure	Time frame
Side effects and noncompliance	—

Countries

Egypt

Contacts

Public ContactMohammed Fakhry

Professor of gastroenterology AlAzhar Univesity Assiut Egypt

mmmmmohammed642@gmail.com00201006795783

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026